MylaPLai-GoldmanMD

Anatomic Pathology, Clinical Pathology

Co-Founder and Chairperson, GeneCentric Therapeutics

Dr. Lai-Goldman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1989
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pathology-Anatomic and Clinical, 1984 - 1988
Icahn School of Medicine at Mount Sinai/Morningside/WestInternship, Internal Medicine, 1983 - 1984
Columbia University Vagelos College of Physicians and SurgeonsClass of 1983

PubMed

19 citations
HLA-B*5701 clinical testing: early experience in the United States.
Hawazin Faruki, Uwe Heine, Trisha Brown, Ruth Koester, Myla Lai-Goldman
Pharmacogenetics and Genomics. 2007-10-01
13 citations
Application of a pharmacogenetic test adoption model to six oncology biomarkers.
Hawazin Faruki, Myla Lai-Goldman
Personalized Medicine. 2010-07-05
63 citations
Oncocytic carcinoid of the kidney associated with periodic Cushing's syndrome.
James Hannah, Barbara Lippe, Myla Lai-Goldman, Sunita Bhuta
Cancer. 1988-05-15

Precision Cancer Drug Startup GeneCentric Acquires Nearby Select ImmunoGenomicsAugust 26th, 2019
RTP-Based GeneCentric Therapeutics Seeks Better Diagnostic Test for Head, Neck CancerAugust 19th, 2019
GeneCentric Therapeutics Acquires Select ImmunoGenomicsAugust 15th, 2019
Join now to see all